Curis Reports Fourth Quarter and Year-End 2013 Financial Results

Go back to Curis Reports Fourth Quarter and Year-End 2013 Financial Results

Roth Reaffirms Curis (CRIS) at Buy; Erivedge, Internal Pipeline Both Ongoing Strengths

February 24, 2014 11:33 AM EST

Roth Capital maintains its Buy rating and $10 price target on Curis (Nasdaq: CRIS) following Q4 results. The company posted Q4 loss of $0.05 per share, versus estimates calling for a loss of $0.07 per share.

Analyst Joseph Pantginis commented, Roche (OTCBB:... More

Curis, Inc. (CRIS) Posts Q4 Loss of 5c/Share

February 20, 2014 7:09 AM EST

Curis, Inc. (NASDAQ: CRIS) reported Q4 EPS of ($0.05), $0.03 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $1.52 million versus the consensus estimate of $1.59 million.

For earnings history and earnings-related data on Curis, Inc. (CRIS) click here.... More